Merck's Keytruda has breast cancer activity; combo trials next
This article was originally published in Scrip
Merck & Co's Keytruda (pembrolizumab) generated an 18.5% overall response rate (ORR) and caused stable disease in 25.9% of hard-to-treat patients with triple-negative breast cancer (TNBC), justifying future studies of the programmed cell death-1 (PD-1) inhibitor in combination with other breast cancer treatments.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.